about
Osteopetrosis and its relevance for the discovery of new functions associated with the skeletonThe T-cell oncogene Tal2 Is a Target of PU.1 and upregulated during osteoclastogenesisTranscription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafBTie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defectsAttenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice.A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis.Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescenceLocalization and function of the anion exchanger Ae2 in developing teeth and orofacial bone in rodents.Murine ameloblasts are immunonegative for Tcirg1, the v-H-ATPase subunit essential for the osteoclast plasma proton pumpThe peripheral cannabinoid receptor knockout mice: an update.RANK, RANKL and osteoprotegerin in bone biology and disease.Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation.TRPV1 deletion impaired fracture healing and inhibited osteoclast and osteoblast differentiation.The osteoclast--what's new?Osteopetrosis: genetics, treatment and new insights into osteoclast function.Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway.Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.OSTM1 bone defect reveals an intercellular hematopoietic crosstalk.Pin1 regulates osteoclast fusion through suppression of the master regulator of cell fusion DC-STAMP.Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-κB and MAPK pathways.In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity.Phospholipase C-related, but catalytically inactive protein (PRIP) up-regulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling.The inhibitory effects of macrolide antibiotics on bone remodeling in chronic rhinosinusitis.
P2860
Q28085259-52C35ED5-65E3-4D86-81F4-D774705AACBBQ28389140-DAADEA51-E68D-42C5-BACD-AECAD6B67F6DQ28506372-FA090EF4-0155-4067-BB05-0C1883098130Q28593934-F7FBAC30-57BC-4230-A189-9ABC8C95B90FQ30827854-14370887-7FDA-4C7B-95CC-9BAAF08C0781Q33754082-9C988F59-A7A2-44F8-B48E-57FDE7BDFC63Q34520133-B428A34C-65AD-46FD-A0FE-CBE0237B71A7Q34573852-BD5890EB-322D-4CC3-9CE4-AB7D4071EAADQ35125019-646B764A-CFE9-405A-9274-79A1C345EC42Q35937152-F86A81AD-7C68-4C44-BB73-B5228C3CC9AFQ36416347-6A136934-C460-4F47-A600-FDB920A9391EQ37199218-EDF7C61A-A8C6-438A-867B-BB0DD18C3DA3Q37233966-259B1D43-BEDA-4007-8099-3604545448F3Q37657821-AA822C8B-0314-4E0D-A601-4E11C0E5ADEDQ37918962-059E0306-D780-4C1E-B0B2-32F37D49304DQ38123371-7A504374-0F8A-4641-9FD5-E453EA77F323Q38759519-1B6632F8-171B-4859-BEF7-C0791BAF24B7Q38815172-F02CABCB-A18A-4E86-968E-A6E5FF23E69AQ41866199-90446B91-129A-4BA4-A3B6-0FC9FD83FB11Q44166987-E4B04AF3-DD82-4386-92ED-147DECFE932AQ46145950-4D5D2A56-EA86-4DF6-AB3B-BC7B58A34E39Q48109630-33982C40-D528-4E5F-9176-405754C919AEQ51085204-676D8057-4719-49E9-ADB5-A528B7F249D5Q53565882-AB987E0A-AF63-4CC7-A5B3-C2D7CA819108
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Osteoclast diseases.
@ast
Osteoclast diseases.
@en
type
label
Osteoclast diseases.
@ast
Osteoclast diseases.
@en
prefLabel
Osteoclast diseases.
@ast
Osteoclast diseases.
@en
P2860
P356
P1476
Osteoclast diseases.
@en
P2093
Miep H Helfrich
P2860
P304
P356
10.1002/JEMT.10375
P577
2003-08-01T00:00:00Z